Anifrolumab Shows Durable Benefits in Achieving LLDAS and Remission in SLE: TULIP and Extension Trial Outcomes
No association between abatacept exposure levels and infection risk in early RA: AVERT-2 trial findings
C-reactive protein-albumin-lymphocyte index identified as a promising biomarker for osteoarthritis risk
Novel mPGES-1 inhibitor, vipoglanstat, shows no benefit for systemic sclerosis-related Raynaud’s phenomenon in clinical trial
Methylprednisolone fails to show benefit in very early systemic sclerosis: ‘Hit Hard and Early’ trial results
